Biktarvy 2023 worldwide sales?

See the DrugPatentWatch profile for Biktarvy

Biktarvy 2023 worldwide sales: what the figure was

Gilead reported worldwide sales for Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) of about $7.6 billion for 2023.[1]

Was that total “worldwide sales,” or a specific country/segment?

The $7.6 billion number is Gilead’s worldwide (global) sales total for the product for 2023, not a single-region figure.[1]

Where to find updates and how sales are tracked

For ongoing tracking by drug and patent coverage context, DrugPatentWatch.com also maintains drug-specific pages that can be useful when pairing commercial performance with patent status and other developments.[2]

Sources

[1] https://www.gilead.com/news-and-media/press-room/press-releases/2024/gilead-reports-2023-results
[2] https://www.drugpatentwatch.com/